[Skip to Navigation]
Sign In
Viewpoint
August 12, 2021

Treatment Options for Relapsed and Refractory Multiple Myeloma: A Luxury or a Challenge?

Author Affiliations
  • 1Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital, Houston
  • 2Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock
  • 3Michael E. Debakey VA Medical Center and Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas
JAMA Oncol. 2021;7(10):1449-1450. doi:10.1001/jamaoncol.2021.2761

Recent advances in the treatment of multiple myeloma (MM) have improved patient outcomes,1 though initial therapy is rarely curative and almost all patients with MM ultimately progress. However, the rapidly evolving treatment landscape for relapsed and refractory MM has made choosing the most appropriate therapy a challenge for many oncologists. The National Comprehensive Cancer Network (NCCN) provides guidelines that are updated to reflect results from the most recent clinical trials to guide this decision-making process. The NCCN has 4 categories of evidence and consensus, with category 1 reflecting a uniform consensus that the intervention is appropriate,2 and the list of NCCN category 1 regimens for the treatment of relapsed and refractory MM is growing.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×